Joseph G. Jurcic, <span>MD</span>

Joseph G. Jurcic, MD

Hematology (Board Certified, Primary Specialty)
Rare Diseases & Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Cancer Care
Medical Oncology (Board Certified)
Office Phone: (212) 305-5098
One of America's Top Doctors
Rated one of New York Magazine's Best Doctors


Dr. Joseph Jurcic is Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. His main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. Research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease.

He is the 2001 recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. He is author or coauthor of more than 80 articles and book chapters, has been the principal investigator on over 25 clinical trials, and regularly lectures at national and international meetings. He serves as a Leukemia Section Editor for The Oncologist. Prior to joining the faculty at Columbia University Medical Center, he was an Attending Physician on the Leukemia Service at Memorial Sloan-Kettering Cancer Center for over 18 years.

Area of Expertise

Please contact the doctor's office to verify that your insurance is accepted.


MD, University of Pennsylvania School of Medicine

1988 University of Pennslyvania School of Medicine

Internship: Barnes Jewish Hospital

Residency: Barnes Jewish Hospital

Fellowship: Memorial Sloan-Kettering Cancer Center


  • Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RAR-a isoform type: Long-term follow-up in acute promyelocytic leukemia.  Blood 2001; 98:2651-2656.
  • Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ÅM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA.  Targeted alpha particle immunotherapy for myeloid leukemia.  Blood 2002; 100:1233-1239.
  • Aliff TB, Maslak PB, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA.  Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.  Cancer 2003; 97:1025-1032.
  • Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg DA, Levitt D, Wedel N.  Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.  Leukemia 2003; 17:314-318.
  • Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas K, Finn RD, Larson SM, O’Reilly RJ, Scheinberg DA, Jurcic JG.  Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.  Bone Marrow Transplant 2003; 32:549-556.
  • Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O’Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JG, Brown R, Ehmann WC, Schulman P, Frankel SR, Scheinberg D.  Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.  J Clin Oncol 2005; 23:4110-4116.
  • Lamanna N, Jurcic JG, Noy A, Maslak PM, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde D, Scheinberg DA, Zelenetz AD, Weiss MA.  Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high quality responses:  Molecular remissions predict for durable complete responses.  J Clin Oncol 2009; 27:491-497.
  • Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL.  Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab:  a phase 1 trial.  Leuk Lymph 2009; 50:1336-1344.
  • Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss MA, Jurcic J, Frattini MG, Scheinberg DA.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T cell responses in patients with complete remission from acute myeloid leukemia.  Blood 2010; 116:171-179.
  • Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas K, Weiss MA, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG.  Sequential cytarabine alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.  Clin Cancer Res 2010; 16:5303-5311.
  • Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248-1254. 
  • Brentjens R, Riviere I, Park JH, Davila ML, Want X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B cell leukemias.  Blood 2011; 118:4817-4828.
  • Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers LE, Jurcic JG. Randomized, phase 2b study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated AML.  Haematologica 2013 98:119-128.
  • Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina HR, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MRM, Young JW, Boulad F, Kernan NA, O’Reilly RJ, Yahalom J, Heller G, Perales M-A.  T-cell depleted stem-cell transplantation for adults with high-risk acute lymphocytic leukemia in 1st complete remission: long-term survival with a decreased risk of graft-versus-host disease.  Biol Blood Marrow Transplant 2013; 19:208-213.
  • Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.  Sci Transl Med 20 March 2013; 5(177):177ra38.
  • Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram S, Orsini J, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, DeBlasio T, Jurcic JG, Nimer S, Peterson LC, Kwaan H, Rowe JM, Douer D, Tallman MS.  Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.  Leuk Res 2013; 37:1004-1009.Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia.  Am Soc Clin Oncol Educ Book. 2014:e126-31.

Herbert Irving Pavilion

161 Fort Washington Avenue Garden Level
New York, NY 10032

Phone: (212) 305-5098

Fax: (212)305-8112

Get Directions

Professor of Medicine at CUMC

  • New York Magazine: Top Doctors Castle Connolly, 2014
  • America's Top Doctors Castle Connolly, 2014, 2013, 2012, 2011, 2010
  • Top Doctors: New York Metro Area Castle Connolly, 2015, 2014, 2013, 2011, 2010, 2009, 2007
  • America's Top Doctors for Cancer Castle Connolly, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007
  • Louise and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research Memorial Sloan-Kettering Cancer Center, 2001
  • Super Doctor